- Home
- BEAT vs ATYR Comparison
BEAT vs ATYR Comparison
Compare BEAT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAT | ATYR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | 16 | 58 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.2M | 51.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BEAT | ATYR |
|---|---|---|
| Price | $0.61 | $0.54 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $5.63 | $3.67 |
| AVG Volume (30 Days) | 492.2K | ★ 2.2M |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $315.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.40 |
| 52 Week High | $4.00 | $7.29 |
Technical Indicators
Market Signals| Indicator | BEAT | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 34.03 | 47.91 |
| Support Level | $0.54 | $0.43 |
| Resistance Level | $0.79 | $0.59 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 10.43 | 36.99 |
Price Performance
Historical ComparisonAbout BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).